Recently, Zhuhai Maidefa Biotechnology Co., Ltd. (hereinafter referred to as "Maidefa") completed tens of millions of yuan in A+ round of financing, which was led by the investment platform of Huafa Group, followed by Taiping Innovation and Ferris Stone. The funds raised this time will be mainly used for the continuous research and development of PHA upstream and downstream pipelines, the expansion and construction of production lines, marketing and team building.
Maidefa is a high-tech enterprise focusing on the research, development, production and commercialization of a new generation of pure bio-based degradable material PHA and its downstream high-value derivative products.
In addition to good thermoplastic processability and mechanical properties, Medfa's unique PHA new biomaterials also have excellent biodegradability, biocompatibility, piezoelectric properties, gas-liquid barrier properties, etc., and can be widely used in many emerging fields such as drug sustained-release carriers, absorbable medical devices, green packaging, 3D printing, water treatment and high-end aquaculture. The company is committed to reducing white pollution and carbon emissions through green biomanufacturing, and providing new solutions to the problem of "stuck neck" of key biomedical materials in China.
Ms. Lv Jinyan, co-founder and CEO of Maidefa, said: "In recent years, China, Europe and the United States and other countries have introduced policies to support synthetic biology and biomanufacturing, and it has become a national strategy.
As an excellent representative of pure bio-based materials in the field of synthetic biology, PHA adopts "open" fermentation, practices the concept of ESG sustainable development, is committed to zero carbon emissions in the whole life cycle, and contributes to the global "carbon neutrality" goal and social sustainable development. This round of financing is of great significance to support the development of Maidfa, thanks to Huafa Group, Taiping Innovation and Ferris Stone for their recognition of Maidfa, we will not forget our original intention, continue to innovate, high-quality development, and provide our product solutions for the green earth, low-carbon environmental protection, and human health.
The relevant person in charge of the investment business of Huafa Group said: synthetic biotechnology is the underlying supporting technology to achieve green manufacturing and "carbon neutrality". As a bio-based material with excellent comprehensive properties, PHA can achieve low carbon in the whole process from production to degradation, and has broad application prospects.
Focusing on the industrialization of PHA biomanufacturing technology, Maidefa has unique advantages in strain development and fermentation technology, and is in a leading position in the industry, we are firmly optimistic about the development prospects of Maidefa, and will work together to promote the high-quality development of China's green biomanufacturing industry in the future.
The relevant person in charge of Taiping Innovation said: As a new generation of bioengineering technology, synthetic biology has broad potential application space in the fields of green carbon peaking and carbon neutrality, medical health, and food consumption.
It is an enterprise in the Guangdong-Macao Traditional Chinese Medicine Science and Technology Industrial Park in Hengqin, which is operated and managed by China Taiping Insurance Group, and has made breakthroughs in the industrialization of synthetic biology. In the future, Taiping Innovation will work with enterprises to continue to promote technological innovation and industrial development in the domestic synthetic biology track.
The person in charge of Ferris Stone Investment said: the development of new biomaterials meets the urgent needs of countries around the world for environmentally sustainable development friendly products, and is expected to replace petrochemical and coal chemical products in the future, and is used in biological, medical, electronic and coating fields, which is a promising new track.
The Maidefa team has deep R&D strength, forward-looking strategic thinking and commercial execution. We are pleased to participate in this round of investment together with outstanding investment institutions such as Huafa Group and Taiping Innovation, and hope to accompany the company to grow into a fully biodegradable products and synthetic biology technology platform enterprise with global influence.
Investor introduction
About Huafa Group
Huafa Group is a comprehensive state-owned enterprise group in Zhuhai and a well-known leading enterprise in China, ranking 169th in the "Top 500 Chinese Enterprises" in 2023, and being selected into the list of "Double Hundred Enterprises" in the reform of state-owned enterprises by the State Council and rated as a national benchmark. Huafa Group now controls 8 listed companies and 2 companies listed on the New Third Board, with assets of more than 720 billion yuan. In the field of industrial investment, Huafa Group focuses on the core tracks of new energy, semiconductors, medical and health care, and its investment entities include Huajin Capital, Infinity, Zhuhai Science and Technology Venture Capital and other platforms, among which Huajin Capital ranks 15th in Qingke's "Top 100 Chinese Private Equity Investment Institutions". Up to now, Huafa Group has successively invested in about 400 industry leaders and high-growth innovative enterprises.
About Taiping Innovation
As a professional private equity investment platform under China Taiping Insurance Group, Taiping Innovation gives full play to the professional advantages of insurance funds and plays the role of a central enterprise in China Taiping, and the funds under its management mainly lay out investment tracks such as medical and health, financial technology, advanced manufacturing, and rural revitalization.
About Ferris Stone
Founded in December 2009, Ferris Stone Investment Holding Co., Ltd. is an equity investment platform under Guangdong Guangrun Group Co., Ltd., which mainly invests in innovative projects in various fields including biomedicine, high-end medical devices and advanced manufacturing, covering industrial investment and financial investment, and is an important part of Guangrun Group's industrial ecology. Guangrun Group has a number of pharmaceutical companies, health care product companies, venture capital companies, and industrial incubation bases, and the innovative biomedical enterprises controlled by the group were successfully listed on the GEM in 2017.